NEW POSSIBILITIES FOR LOCAL THERAPY OF BACK PAIN SYNDROME

Purpose of study – to examine effectiveness and tolerability of therapy рatch NANOPLAST forte in comparison with “placebo” patch in patients with back pain syndrome in conditions of prospective comparative randomized study, approved by the local ethics committee.

Materials and methods. The study included 60 patients with acute/ recrudescence of chronic primary back pain syndrome, there were 30 patients in each group, which were comparable in main clinical parameters. A primary effectiveness criterion was reduction of back pain syndrome intensity at rest and during movements by no less than 50% from initial level according to visual analogue scale (mm). Overall effectiveness of NANOPLAST forte patch was evaluated separately by doctor and patient on the 10th day according to the following grading: significant improvement; improvement; absence of effect. A need for administration of non-steroidal anti-inflammatory drugs (NSAID) was assessed during the study. A patch was applied once a day for 12 h (from 9 to 21 h). Tolerability of NANOPLAST forte patch and “Placebo” patch was evaluated according to frequency and severity of local and/or systemic adverse events, and to tolerability grading: very good effect, good effect, satisfactory effect, absence of effect. Frequency of achievement of not less than 50% of back pain reduction at rest was significantly higher in NANOPLAST forte group than in “placebo” group (96,6% versus 23.3% respectively; р=0.001, Pearson’s chi-squared test), as well as during movements (93,3% versus 40% respectively; р=0.001, Pearson’s chi-squared test). Evaluation of treatment effectiveness was higher in NANOPLAST forte group in comparison with “Placebo” group in the opinion of both patient and doctor. Pain intensity during walking and at rest statistically significantly decreased according to visual analogue scale (p<0.05, Wilcoxon test) by the 10th day  in NANOPLAST forte group. A need for additional administration of non-steroidal anti-inflammatory drugs was statistically significantly lower in NANOPLAST forte group in comparison with “Placebo” group (р<0.05, Pearson’s chi-squared test). All patients completed the study. Adverse events related to use of NANOPLAST forte patch were not detected.

Conclusion. NANOPLAST forte can be recommended as an effective and safe method of local therapy in case of back pains. 

1. Шостак Н.А., Правдюк Н.Г. Дорсопатии – новый взгляд на проблему диагностики и лечения. Современная ревматология 2010;4(1):28–31. [Shostak N.A., Pravdyuk N.G. Dorsopathy is a new approach to the problem of diagnosis and treatment. Sovremennaya revmatologiya = Modern Rheumatology 2010;4(1):28–31. (In Russ.)].

2. Шостак Н.А. Алгология как междисциплинарная проблема современной медицины. Клиницист 2008;(1):4–9. [Shostak N.A. Algologia as an interdisciplinary problem in modern medicine. Klinitsist = Clinician 2008;(1):4–9. (In Russ.)].

3. Nijs J., Apeldoorn A., Hallegraeff H. et al. Low back pain: guidelines for the clinical classification of predominant neuropathic, nociceptive, or central sensitization pain. Pain Physician 2015;18(3):333–46. PMID: 26000680.

4. Шостак Н.А., Правдюк Н.Г. Боль в нижней части спины: дифференциальная диагностика и лечение. Лечебное дело 2015;(2):77–82. [Shostak N.A., Pravdyuk N.G. Pain in lower back: differential diagnosis and treatment. Lechebnoe delo = Medicine 2015;(2): 77–82. (In Russ.)].

5. Шостак Н.А., Клименко А.А., Демидова Н.А., Кондрашов А.А. Проблема кардиобезопасности нестероидных противовоспалительных препаратов. Терапевтический архив 2016;88(5): 113–7. [Shostak N.A., Klimenko A.A., Demidova N.A., Kondrashov A.A. The problem of cardiometabolic nonsteroidal anti-inflammatory drugs. Terapevticheskiy arkhiv = Therapeutic Archive 2016;88(5):113–7. (In Russ.)].

6. Каратеев А.Е., Насонов Е.Л., Яхно Н.Н. и др. Клинические рекомендации «Рациональное применение нестероидных противовоспалительных препаратов (НПВП) в клинической практике». Современная ревматология 2015;9(1):4–23. [Karateev A.E., Naso- nov E.L., Yakhno N.N. et al. Clinical guidelines “Rational use of nonsteroidal anti-inflammatory drugs (NSAIDs) in clinical practice”. Sovremennaya revmatologiya = Modern Rheumatology 2015;9(1):4–23. (In Russ.)].

7. Lanza F.L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal аntiinflammatory drugs. Scand J Gastroenterol Suppl 1989;163:24–31. PMID: 2683026.

8. Ананьева Л.П., Панасюк Е.Ю., Денисов Л.Н., Кузин А.В. Боли в нижней части спины в практике ревматолога, локальная терапия Версатисом. Справочник поликлинического врача 2007;(9):43–6. [Anan’eva L.P., Pana- syuk E.Yu., Denisov L.N., Kuzin A.V. Pain in the lower back in a rheumatologist’s practice, local therapy by Versatis. Spravochnik poliklinicheskogo vracha = Handbook of Оutpatient Physician 2007;(9):43–6. (In Russ.)].

9. Evans J.M., MacDonald T.M. Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage? Drugs Aging 1996;9(2):101–8. PMID: 8820796.

10. Цветкова Е.A., Денисов Л.H. Новое направление локального лечения остео артроза коленных суставов. Клиницист 2014;(2):51–4. [Tsvetkova E.A., Denisov L.N. New direction for local treatment of osteoarthritis of the knee. Klinitsist = Clinician 2014;(2):51–4. (In Russ.)].